Neurogene's top three insider shareholders as of June 18, 2026 are Jonathan G Drachman (President And Ceo, 2.37Mn shares), Biocapital Gp, Llc Samsara (TenPercentOwner, 1.72Mn shares), Bros. Advisors Lp Baker (Director, 1.66Mn shares).
| Holder | Position | Shares (Direct) | Shares (Indirect) | Report Date |
|---|---|---|---|---|
| Bros. Advisors Lp Baker | - | 0 | 1,658,190 | 10 Oct, 2023 |
| Christine Mikail Cvijic | President And Cfo | 103,240 | 0 | 30 Mar, 2026 |
| Jonathan G Drachman | President And Ceo | 2,348,686 | 25,000 | 26 Aug, 2021 |
| Rachel Mcminn | Chief Executive Officer | 1,344,307 | 0 | 30 Mar, 2026 |
| Priti Patel | Chief Medical Officer | 37,313 | 0 | 04 Apr, 2023 |
| Biocapital Gp, Llc Samsara | - | 0 | 1,717,127 | 27 Nov, 2024 |
| Sean Michael Smith | Interim Cfo, Prin Acct Off | 21,637 | 0 | 14 Aug, 2023 |
| Julie Jordan | Chief Medical Officer | 12,472 | 0 | 30 Mar, 2026 |
| Stuart Cobb | Chief Scientific Officer | 30,497 | 0 | 17 Mar, 2026 |
* Please note that the shares above only reflect shares from the fund portfolio and the institutional portfolio. Shares from the personal portfolio are excluded from this Institutional Ownership Page. See these insiders' latest transactions here on Insider Page.
| Transaction Date | Insider Name | Security Class | Transaction Type | Shares Traded | Price | Shares Remaining | Ownership | Code |
|---|---|---|---|---|---|---|---|---|
| 26 Mar, 2026 | Rachel Mcminn | Common Stock | D | 3,352 | $22.07 | 1,344,307 | D | S |
| 26 Mar, 2026 | Christine Mikail Cvijic | Common Stock | D | 2,558 | $21.62 | 103,240 | D | S |
| 26 Mar, 2026 | Julie Jordan | Common Stock | D | 828 | $21.89 | 12,472 | D | S |
| 13 Mar, 2026 | Stuart Cobb | Common Stock | D | 3,991 | $20.41 | 33,303 | D | S |
| 13 Mar, 2026 | Christine Mikail Cvijic | Common Stock | D | 2,387 | $20.42 | 107,456 | D | S |
| 13 Mar, 2026 | Christine Mikail Cvijic | Common Stock | D | 1,395 | $21.25 | 106,061 | D | S |
| 13 Mar, 2026 | Stuart Cobb | Common Stock | D | 2,658 | $21.34 | 30,645 | D | S |
| 13 Mar, 2026 | Christine Mikail Cvijic | Common Stock | D | 263 | $22.02 | 105,798 | D | S |
| 13 Mar, 2026 | Stuart Cobb | Common Stock | D | 148 | $22.08 | 30,497 | D | S |
| 27 Feb, 2026 | Christine Mikail Cvijic | Common Stock | D | 4,800 | $25.11 | 109,843 | D | S |
| 20 Feb, 2026 | Cory S. Freedland | Non-Qualified Stock Option (right to buy) | A | 12,050 | $0.00 | 12,050 | D | A |
| 20 Feb, 2026 | Julie Jordan | Common Stock | A | 4,900 | $0.00 | 13,300 | D | A |
| 20 Feb, 2026 | Christine Mikail Cvijic | Common Stock | A | 22,000 | $0.00 | 114,643 | D | A |
| 20 Feb, 2026 | Rohan Palekar | Non-Qualified Stock Option (right to buy) | A | 12,050 | $0.00 | 12,050 | D | A |
| 20 Feb, 2026 | Robert Baffi | Non-Qualified Stock Option (right to buy) | A | 12,050 | $0.00 | 12,050 | D | A |
| 20 Feb, 2026 | Rachel Mcminn | Common Stock | A | 25,900 | $0.00 | 1,347,659 | D | A |
| 20 Feb, 2026 | Rohan Palekar | Non-Qualified Stock Option (right to buy) | A | 12,050 | $0.00 | 12,050 | D | A |
| 20 Feb, 2026 | Stuart Cobb | Common Stock | A | 16,500 | $0.00 | 37,294 | D | A |
| 20 Feb, 2026 | Julie Jordan | Stock Option (Right to Buy) | A | 29,600 | $0.00 | 29,600 | D | A |
| 20 Feb, 2026 | Rachel Mcminn | Stock Option (Right to Buy) | A | 155,100 | $0.00 | 155,100 | D | A |